Quick Answer
NANOVIRICIDES, INC. reported Net Income of -$9.47 million for fiscal year 2025.
NANOVIRICIDES, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$9.47M -14.1% |
-$8.29M +3.4% |
-$8.59M -5.9% |
-$8.11M +8.1% |
-$8.82M +34.4% |
-$13.45M -59.6% |
| Diluted EPS | -$0.63 +10.0% |
-$0.70 +5.4% |
-$0.74 -5.7% |
-$0.70 +13.6% |
-$0.81 | — |
| Total Assets | $8.82M -31.2% |
$12.82M -24.1% |
$16.90M -28.1% |
$23.49M -22.4% |
$30.26M +26.5% |
$23.91M +77.8% |
| Cash and Equivalents | $1.56M -67.5% |
$4.80M -41.1% |
$8.15M -42.1% |
$14.07M -31.4% |
$20.52M +49.7% |
$13.71M +436.5% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $7.52M -34.4% |
$11.46M -22.9% |
$14.87M -35.6% |
$23.08M -22.8% |
$29.91M +37.5% |
$21.76M +105.3% |
| R&D Expense | $5.55M +2.1% |
$5.44M -14.9% |
$6.39M +10.5% |
$5.78M -5.4% |
$6.11M +30.2% |
$4.70M -20.7% |
| Operating Income | -$9.59M -12.6% |
-$8.52M +4.8% |
-$8.94M -10.2% |
-$8.11M +7.2% |
-$8.74M -9.3% |
-$8.00M +7.7% |
| Shares Outstanding | 16.61M +26.3% |
13.14M +12.4% |
11.70M +0.9% |
11.59M +0.7% |
11.52M +26.8% |
9.08M +136.2% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2012 | $0.00 | — | — |
| Net Income | December 31, 2025 | -$2.22M | -9.5% | -24.4% |
| Diluted EPS | December 31, 2025 | -$0.11 | +21.4% | -10.0% |
| Total Assets | December 31, 2025 | $12.27M | +6.0% | +46.8% |
| Cash and Equivalents | December 31, 2025 | $5.15M | +30.1% | +357.5% |
| Long-Term Debt | March 31, 2015 | $0.00 | -100.0% | -100.0% |
| Stockholders Equity | December 31, 2025 | $11.07M | +6.6% | +54.3% |
| R&D Expense | December 31, 2025 | $1.12M | -3.3% | +12.6% |
| Operating Income | December 31, 2025 | -$2.23M | -8.5% | -24.3% |
| Shares Outstanding | December 31, 2025 | 21.60M | +38.1% | +23.0% |
- NANOVIRICIDES, INC. reported Net Income of -$9.47 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed a decrease of -14.1% in Net Income compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Diluted EPS of $0.63 per share (loss) for fiscal year 2025.
- NANOVIRICIDES, INC. showed an increase of +10.0% in Diluted EPS compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Total Assets of $8.82 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed a decrease of -31.2% in Total Assets compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Cash and Equivalents of $1.56 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed a decrease of -67.5% in Cash and Equivalents compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Long-Term Debt of $0.00 for fiscal year 2015.
- NANOVIRICIDES, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Stockholders Equity of $7.52 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed a decrease of -34.4% in Stockholders Equity compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported R&D Expense of $5.55 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed an increase of +2.1% in R&D Expense compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Operating Income of -$9.59 million for fiscal year 2025.
- NANOVIRICIDES, INC. showed a decrease of -12.6% in Operating Income compared to the prior fiscal year.
- NANOVIRICIDES, INC. reported Shares Outstanding of 16.61 million shares for fiscal year 2025.
- NANOVIRICIDES, INC. showed an increase of +26.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: